FDC Ltd

FDC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

FDC Ltd

₹ 465 1.81%
21 May 2:11 p.m.
fdcindia.com BSE: 531599 NSE: FDC
About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

Key Points

Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]

Website BSE NSE
  • Market Cap ₹ 7,566 Cr.
  • Current Price ₹ 465
  • High / Low ₹ 659 / 359
  • Stock P/E 27.5
  • Book Value ₹ 141
  • Dividend Yield 1.12 %
  • ROCE 18.4 %
  • ROE 14.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 11.8% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare BSE SmallCap BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
342 341 495 445 409 435 536 486 458 462 638 514 464
294 322 417 378 360 386 414 410 374 406 492 444 417
Operating Profit 48 19 78 67 49 49 122 76 84 56 147 70 47
OPM % 14% 6% 16% 15% 12% 11% 23% 16% 18% 12% 23% 14% 10%
13 10 19 13 18 7 29 27 25 20 28 35 19
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 10 10 10 10 10 10 10 11 14 13
Profit before tax 51 19 87 69 57 45 141 93 98 65 163 90 51
Tax % 30% 45% 19% 25% 28% 32% 22% 25% 19% 29% 27% 20% 28%
36 10 71 52 41 31 110 70 79 46 119 72 37
EPS in Rs 2.11 0.62 4.26 3.12 2.46 1.85 6.62 4.29 4.87 2.84 7.31 4.42 2.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
772 845 888 994 1,013 1,074 1,089 1,341 1,331 1,525 1,784 1,943 2,078
591 638 690 765 769 841 860 1,038 997 1,271 1,533 1,604 1,759
Operating Profit 181 207 199 229 243 233 229 304 334 254 251 339 320
OPM % 23% 24% 22% 23% 24% 22% 21% 23% 25% 17% 14% 17% 15%
46 39 46 39 44 45 42 57 95 76 50 102 102
Interest 2 3 2 1 1 1 1 3 3 3 4 4 4
Depreciation 28 25 39 34 35 35 33 37 38 37 39 40 49
Profit before tax 198 218 204 232 252 241 237 320 388 289 258 396 369
Tax % 22% 38% 27% 27% 25% 28% 28% 25% 22% 25% 25% 23%
155 135 148 169 189 174 170 240 301 216 194 305 274
EPS in Rs 8.49 7.61 8.33 9.48 10.60 9.95 9.74 14.03 17.85 12.82 11.70 18.75 16.85
Dividend Payout % 26% 30% 27% 24% 21% 0% 0% 6% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 9%
5 Years: 12%
3 Years: 13%
TTM: 8%
Compounded Profit Growth
10 Years: 9%
5 Years: 11%
3 Years: 1%
TTM: -5%
Stock Price CAGR
10 Years: 11%
5 Years: 14%
3 Years: 22%
1 Year: -5%
Return on Equity
10 Years: 14%
5 Years: 13%
3 Years: 12%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 18 18 18 18 18 18 18 17 17 17 17 16 16
Reserves 766 827 919 1,065 1,252 1,259 1,428 1,530 1,717 1,940 1,965 2,081 2,275
3 3 2 1 1 1 1 15 15 32 28 21 20
179 211 210 182 197 228 194 250 207 281 333 350 376
Total Liabilities 966 1,059 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,688
289 284 393 675 678 674 682 674 689 705 699 680 805
CWIP 7 18 29 20 6 13 12 24 19 105 198 261 143
Investments 416 417 489 325 491 471 585 665 790 886 806 843 1,066
254 340 237 246 293 348 360 451 458 575 640 684 674
Total Assets 966 1,059 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,688

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
150 150 128 174 154 150 112 250 207 162 155 221
-107 -55 -89 -73 -144 21 -121 -98 -77 -145 11 -17
-63 -75 -48 -97 0 -169 -0 -142 -129 -10 -180 -202
Net Cash Flow -20 19 -9 4 11 1 -8 10 1 7 -14 2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 20 26 25 23 27 28 29 34 30 20 25 22
Inventory Days 117 116 132 134 148 166 184 180 189 210 183 216
Days Payable 72 90 94 84 81 101 82 101 68 94 99 103
Cash Conversion Cycle 66 51 64 72 94 93 131 113 152 135 109 135
Working Capital Days 24 2 11 21 23 29 45 41 50 47 49 54
ROCE % 23% 25% 21% 22% 21% 19% 17% 21% 22% 15% 13% 18%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.50% 69.49% 69.49% 69.49% 69.49% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66%
4.34% 3.99% 3.77% 3.80% 2.06% 2.42% 2.43% 2.65% 2.51% 2.62% 2.67% 2.56%
6.07% 6.77% 7.76% 8.27% 9.13% 8.12% 7.76% 6.94% 6.72% 6.02% 6.08% 6.37%
20.09% 19.75% 18.98% 18.44% 19.32% 19.80% 20.15% 20.76% 21.11% 21.71% 21.60% 21.42%
No. of Shareholders 65,31863,17259,87157,01256,71756,92855,34152,37750,63455,40055,22853,880

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls